期刊文献+

超声引导下PTC针穿刺无水乙醇注射治疗继发性甲状旁腺功能亢进的临床观察 被引量:9

Clinical observation of percutaneous ethanol injection by PTC needle under ultrasonic guidance treating secondary hyperparathyroidism
下载PDF
导出
摘要 目的观察终末期肾衰竭患者继发性甲状旁腺功能亢进使用超声引导下PTC针穿刺无水乙醇注射治疗的疗效。方法选择28例维持性血液透析继发性甲状旁腺功能亢进(iPTH≥44 pmol/mL)的患者,在超声引导下使用PTC针进行甲状旁腺穿刺,无水乙醇注射治疗,观察注射前后iPTH、碱性磷酸酶、血清钙、磷及多普勒超声甲状旁腺血流的变化。结果 PEITP治疗前后对比iPTH明显下降,皮肤瘙痒明显缓解,骨关节痛减轻,甲状旁腺增生腺体的血流明显减少。有明显统计学差异。结论 PEITP技术目前在开展甲状旁腺切除(PTX)条件不够的单位依然是治疗难治性SHPT的有效方法。 Objective To observe effect of percutaneous ethanol injection therapy(PEITP) by PTC needle under ultrasonic guidance treating for secondary hyperparathyroidism(SHPT) of end-stage renal disease.Methods Twenty-eight hemodialysis patients with secondary hyperparathyroidism were treated with percutaneous ethanol injection by PTC needle under ultrasonic guidance.The parathyroid hormone,alkaline phosphatase,serum calcium,phosphorus,and blood flow signals of the gland under ultrasonic guidance were observed before and after treatment.Results The levels of iPTH and the blood flow signals of the gland were significantly decreased while the symptoms such as the skin pruritus,bone-arthrosis pain were improved significantly after treatment.There are significant differences.Conclusion PEITP is an efficient treatment for SHPT while not every hospital has enough facility to support parathyroidectomy(PTX).
出处 《实用临床医药杂志》 CAS 2011年第15期30-32,共3页 Journal of Clinical Medicine in Practice
关键词 甲状旁腺功能亢进 继发性 超声引导 穿刺 hyperparathyroidism secondary ultrasonic guidance injection
  • 相关文献

参考文献11

  • 1De Boer I H,Gorodetskaya I,Young B,et al.The Severity of Secondary Hyperparathyroidism in Chronic Renal Insufficiency is GFR-Dependent,Race-Dependent,andAssociated with Cardiovascular Disease[J].Am Soc Nephrol,2002,13(11):2762.
  • 2Rodriguez M,Nemeth E,Martin D.The calcium-sensing receptor:a key factor in the pathogenesis of secondary hyperparathyroidism[J].Am J Physiol Renal Physiol,2005,288(2):253.
  • 3Tokumoto M,TaniguchiM,Matsuo D,et al.Parathyroid cell growth in patients with advanced secondary hyperparathyroidism:vitamin Drecep tor,calcium sensing recep tor,and cell cycle regulating factors[J].Ther Apher Dial,2005,9(1):27.
  • 4Hruska K A,Steven 1,Teitelbaum.Renal osteodystrophy[J].N Engl J Med,1995,333(3):166.
  • 5Raggi P,Boulay A,Chasan-Taber S,et al.Cardiac calcification in adult hemodialysis patients:A link between ESRD and cardiovascular disease[J].J Am Coll Cardiol,2002,39(4):695.
  • 6印荻,章旭.慢性肾脏病患者的颈动脉粥样硬化及心脏瓣膜钙化[J].临床肾脏病杂志,2009(6):285-286. 被引量:2
  • 7Drueke T B,Eckardt K U.Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients[J].Nephrol Dial Transp lant,2002,17(5):28.
  • 8Fukuda N,Tanaka H,Tominaga Y,et al.Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronicuremic patients[J].J Clin Invest,1993,92:1436.
  • 9Barros Gueiros J E,Chammas M C,Gerhard R,et al.Percutaneous ethanol(PEIT) and calcitrol(PCIT) injection therapy are ineffective in treating severe secondary hyperparathyroidism[J].Nephrol Dial Transplant,2004,19 (3):657.
  • 10TanakaM,ItohK,MatsushitaK,et al.Efficacy of percutaneous ethanol injection therapy for secondary hyperparathyroidism in pationts on hemodialysis as evaluated by parathyroid hormone levels according to K/DOQI guidelines[J].Ther Apher Dial,2005,9(1):48.

二级参考文献16

  • 1杨小兵,侯凡凡,武强,周华,刘郑荣,杨燕,张训.慢性肾脏病患者晚期氧化蛋白产物血症及其与动脉粥样硬化的关系[J].中华内科杂志,2005,44(5):342-346. 被引量:41
  • 2Malberti F, Ravani P. Disturbances of mineral metabolism and vascular calcification in dialysis patients. G Ital Nefrol, 2004,21 238-244.
  • 3Prati P, Vanuzzo D, Casaroli M, et al. Determinants of carotid plaque occurrence. A long-term prospective population study:The san daniele project. Cerebrovasc Dis, 2006,22 : 416.
  • 4Debette S, Lambert JC,Gariepy J,et al. New insight into the association of apolipoprotein E genetic variants with carotid plaques and intima media thickness. Stroke,2006,37:2917.
  • 5Zoccali G, Mallamaci F, Tripepi. Inflammation and atherosclerosis in end-stage renal disease. Blood Purif, 2003,21 : 29-36.
  • 6K/DOQI. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Disease, 2002,39 : 1-266.
  • 7Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension, 2003,42: 1206- 1252.
  • 8Kamyar KZ,Gladys B, Michael H, et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int, 2003,63 : 793-808.
  • 9Uzu T, Harada T, Yamamoto R, et al. Thiazide diuretics enhance nocturnal blood pressure fall and reduce proteinuria in patients with IgA nephropathy treated with angiotensin Ⅱ modulators. J Am Soc Nephrol, 2003,14: 21.
  • 10Xue JL, Ebben Jp, Peter WL, et al. Correction of anemia with erythropoietin during the two year pre ESRD period: post-ESRD mortality. J Am Soc Nephrol,2001,12:259.

共引文献1

同被引文献170

引证文献9

二级引证文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部